Previous 10 | Next 10 |
Over the past couple of months, investors have been taken on the wildest roller-coaster ride in the stock market's history. The coronavirus disease 2019 (COVID-19) pandemic has created uncertainty and labor market disruption on a scale that's never been seen in the modern era. As a result, the...
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) were down 13% at 3 p.m. EDT on Friday after the company disclosed that the Food and Drug Administration plans to p ostpone an advisory committee meeting to review obeticholic acid as a treatment for liver fibrosis due to nonalcoholic stea...
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are plunging on Friday after the company announced some bad news regarding its new drug application (NDA) for Ocaliva as a treatment for fibrosis (buildup of scar tissue) in the liver due to nonalcoholic steatohepatitis (NASH). Intercept's s...
Recon Technology (NASDAQ: RCON ) -38% on ~$2.1M registered direct offering . More news on: Recon Technology, Ltd., Geron Corporation, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
For 11 years, it was relatively smooth sailing for investors. Following the March 2009 stock market bottom, all three major U.S. indexes ended up at least quadrupling in value, if not delivering even more robust returns. Then the coronavirus disease 2019 (COVID-19) pandemic came along and disrup...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q1 2020 Earnings Call May 11, 2020 , 8:30 a.m. ET Operator Continue reading
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2020 Earnings Conference Call May 11, 2020, 08:00 AM ET Company Participants Lisa M. DeFrancesco - Vice President Investor Relations Mark E. Pruzanski - President, Chief Executive Officer & Director Jerome B. Durso - Chief Operating O...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Intercept Pharmaceuticals (NASDAQ: ICPT) , a mid-cap liver disease specialist, saw its shares rise by a healthy 40.3% over the course of April, according to data from S&P Global Market Intelligence . Most impressively, the biotech's shares even outperformed the broader iShares...
Intercept Pharmaceuticals ( ICPT ) Q1 results : More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...